BridgeBio Pharma BBIO Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's accrued manufacturing costs?
- BridgeBio Pharma (BBIO) reported accrued manufacturing costs of $39.34M in Q1 2026.
- How has BridgeBio Pharma's accrued manufacturing costs changed year-over-year?
- BridgeBio Pharma's accrued manufacturing costs increased by 17.6% year-over-year, from $33.45M to $39.34M.
- What is the long-term trend for BridgeBio Pharma's accrued manufacturing costs?
- Over 5 years (2020 to 2025), BridgeBio Pharma's accrued manufacturing costs has grown at a 20.9% compound annual growth rate (CAGR), from $29.68M to $76.7M.